Lukas Gilgen, who until now served as Transaction Lead Enterprise Projects with Novartis International AG, has been appointed as the new CFO of MorphoSys AG.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.25 EUR | -0.66% | -.--% | +97.79% |
Aug. 29 | MorphoSys AG Announces Changes in the Composition of the Supervisory Board | CI |
Aug. 29 | MorphoSys AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 | CI |
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MOR Stock
- MOR Stock
- News MorphoSys AG
- MorphoSys AG Appoints Lukas Gilgen as CFO